Intervention

natalizumab

ClinicalTrials.gov intervention label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 18 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials18
Recruiting0
Common conditions6
Lead sponsors shown3
Advertisement

Clinical trials

18 shown
The 'Wearing Off' Effect of DMTNCT05627271 · 2023-01-10
COMPLETED
Clinical Disease Activity With Long Term Natalizumab TreatmentNCT02677077 · 2015-12-31
COMPLETED
Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With NatalizumabNCT02386566 · 2015-03-20
COMPLETED
Natalizumab Subcutaneous Immunogenicity and Safety StudyNCT02142192 · 2014-12-01
TERMINATED
Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) ParticipantsNCT02342704 · 2014-11-30
TERMINATED
Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other TherapiesNCT02241785 · 2014-09-30
TERMINATED
Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)NCT02159573 · 2014-07-01
COMPLETED
Safety and Efficacy in Pediatric MS Patients Prescribed TysabriNCT02137109 · 2014-03-01
COMPLETED
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative ParticipantsNCT01485003 · 2012-02-07
COMPLETED
Ireland Natalizumab (TYSABRI) Observational ProgramNCT01943526 · 2011-11-30
COMPLETED
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple SclerosisNCT01416181 · 2011-09-13
TERMINATED
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple SclerosisNCT01416155 · 2010-10-01
COMPLETED
Treatment Interruption of NatalizumabNCT01071083 · 2010-03-01
COMPLETED
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With NatalizumabNCT01070836 · 2010-03-01
COMPLETED
Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple SclerosisNCT01065727 · 2010-03-01
COMPLETED
Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)NCT00559702 · 2007-10-01
COMPLETED
A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201NCT00831649 · 2004-09-01
TERMINATED
Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving MethotrexateNCT00083759 · 2004-05-01
TERMINATED

Trial status mix

COMPLETED12
TERMINATED6

Phase mix

PHASE25
PHASE42
NA1
PHASE11
PHASE31
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.